Danaher Corporation · DHR · FY2026 Q2 · Calendar Q3 2026
Danaher Q2 Beats EPS and Revenue, Raises FY Guidance; Bioprocessing Shipment Delays Pressure Stock
Danaher delivered a Q2 beat with revenue of $6.3 billion (core growth +4.5% YoY) and adjusted EPS of $1.94, ahead of the $1.85 consensus estimate. The company raised full-year adjusted EPS guidance to $8.45–$8.60 from $8.35–$8.55. Despite these positives, shares fell approximately 11% on report day with 6.6x normal volume — the market focused on bioprocessing shipment timing delays that pressured near-term equipment revenue conversion, even though underlying order growth remained in the mid-teens. The Masimo acquisition closed in early June, earlier than expected, and is immediately accretive. New product launches across life sciences (Biacore 8S, SCIEX novus V55) and diagnostics (Access pTau217 Alzheimer's blood assay) broaden the growth base. The stock has since recovered most of the initial decline, trading at $199.08 as of July 28. With a bullish score of 82 and confident…
Company context
Snapshot as of publicationDanaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems.…
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeFollow DHR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Core revenue growth accelerated to +4.5% YoY from +0.5% in Q1, and free cash flow improved to $1.3 billion from $1.1 billion. The Masimo acquisition — pending in Q1 — closed in early June, ahead of the expected mid-year timeline, and is now contributing to results. Full-year adjusted EPS guidance was raised from $8.35–$8.55 to $8.45–$8.60. However, bioprocessing shipments experienced timing delays, a reversal from Q1 when equipment orders were up over 30% YoY. A new pending acquisition of StatLab by Leica Biosystems was disclosed, expected to close by end of 2026. The product launch focus shifted from Q1's Fibro dT and APS to Biacore 8S, SCIEX novus V55, and the Access pTau217 blood-based Alzheimer's assay. CapEx outlook moved from not mentioned to increasing, driven by bioprocessing capacity and a new Singapore plant.
Guidance delta
Full-year adjusted EPS guidance raised from $8.35–$8.55 (Q1 midpoint $8.45) to $8.45–$8.60 (Q2 midpoint $8.525), an increase of approximately $0.08 at the midpoint. Guidance sentiment: raised. Management expressed confidence in the trajectory supported by the Masimo contribution, new product launches, and continued bioprocessing demand.
Key takeaways
- Q2 revenue of $6.3B with core growth of 4.5% YoY and free cash flow of $1.3B
- Adjusted EPS of $1.94 beat consensus of $1.85 by 4.9%; revenue of $6.27B beat by 2.4%
- Full-year adjusted EPS guidance raised to $8.45–$8.60 from $8.35–$8.55
- Masimo acquisition closed in early June, earlier than expected, and is immediately accretive
- Bioprocessing shipments faced timing delays, but underlying order growth remains in the mid-teens
Management priorities
- Integrate Masimo and realize its EPS contribution and synergies across diagnostics
- Close the StatLab acquisition by end of 2026
- Continue product pipeline launches in life sciences and diagnostics
- Invest in bioprocessing capacity expansion including a new Singapore plant
- Leverage AI to enhance the Danaher Business System and drive margin expansion
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-07-21T16:03:40.442608+00:00
- FN2 earnings calendar · 2026-07-28T01:23:15.070317+00:00
- Polygon adjusted daily market bars · 2026-07-28T21:24:58.770182+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T21:24:58.766967+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.